A new updated prognostic index for patients with brain metastases (BMs) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore project
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
INTRODUCTION: Palliative WBRT is the main treatment for multiple BMs. Recent studies report no benefit in survival after WBRT compared to palliative supportive care in patients (pts) with poor prognosis. A new era of systemic treatment strategies based on targeted therapies are improving the prognosis of patients with BMs. The purpose of this study is to develop a prognostic score in palliative pts with BMs who undergo WBRT in this new setting.
METHODS: 239 pts with BMs who received palliative WBRT between 2013-2022 in our center were analyzed retrospectively. The score was designed according to the value of the β coefficient of each variable with statistical significance in the multivariate model using Cox regression. Once the score was established, a comparison was performed according to Kaplan-Meier and was analyzed by log-rank test.
RESULTS: 149 pts (62.3%) were male and median (m) age was 60 years. 139 (58,2%) were lung cancer and 35 (14,6%) breast cancer. All patients received 30Gys in 10 sessions. m overall survival (OS) was 3,74 months (ms). 37 pts (15,5%) had a specific target mutation. We found that 62 pts were in group < 4 points with mOS 6,89 ms (CI 95% 3,18-10,62), 84 in group 4-7 points with mOS 4,01 ms (CI 95% 3,40-4,62) and 92 pts in group > 7 points with mOS 2,72 ms (CI 95% 1,93-3,52) (p < 0,001).
CONCLUSIONS: METASNCore items are associated with OS and they could be useful to select palliative pts to receive WBRT. More studies are necessary to corroborate our findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of neuro-oncology - (2024) vom: 27. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Flores-Paco, Pablo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Brain metastases |
|---|
| Anmerkungen: |
Date Revised 28.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s11060-024-04618-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370285492 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370285492 | ||
| 003 | DE-627 | ||
| 005 | 20240329001827.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11060-024-04618-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM370285492 | ||
| 035 | |a (NLM)38539006 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Flores-Paco, Pablo |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A new updated prognostic index for patients with brain metastases (BMs) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore project |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a INTRODUCTION: Palliative WBRT is the main treatment for multiple BMs. Recent studies report no benefit in survival after WBRT compared to palliative supportive care in patients (pts) with poor prognosis. A new era of systemic treatment strategies based on targeted therapies are improving the prognosis of patients with BMs. The purpose of this study is to develop a prognostic score in palliative pts with BMs who undergo WBRT in this new setting | ||
| 520 | |a METHODS: 239 pts with BMs who received palliative WBRT between 2013-2022 in our center were analyzed retrospectively. The score was designed according to the value of the β coefficient of each variable with statistical significance in the multivariate model using Cox regression. Once the score was established, a comparison was performed according to Kaplan-Meier and was analyzed by log-rank test | ||
| 520 | |a RESULTS: 149 pts (62.3%) were male and median (m) age was 60 years. 139 (58,2%) were lung cancer and 35 (14,6%) breast cancer. All patients received 30Gys in 10 sessions. m overall survival (OS) was 3,74 months (ms). 37 pts (15,5%) had a specific target mutation. We found that 62 pts were in group < 4 points with mOS 6,89 ms (CI 95% 3,18-10,62), 84 in group 4-7 points with mOS 4,01 ms (CI 95% 3,40-4,62) and 92 pts in group > 7 points with mOS 2,72 ms (CI 95% 1,93-3,52) (p < 0,001) | ||
| 520 | |a CONCLUSIONS: METASNCore items are associated with OS and they could be useful to select palliative pts to receive WBRT. More studies are necessary to corroborate our findings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Brain metastases | |
| 650 | 4 | |a Palliative medicine | |
| 650 | 4 | |a Prognostic factors | |
| 650 | 4 | |a Supportive care | |
| 650 | 4 | |a Whole brain radiotherapy | |
| 700 | 1 | |a Vargas-Aliaga, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Guevara, María Geraldina |e verfasserin |4 aut | |
| 700 | 1 | |a Lopera, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz, Lucía Rodríguez |e verfasserin |4 aut | |
| 700 | 1 | |a López-Herrero, María |e verfasserin |4 aut | |
| 700 | 1 | |a Camús, Juan Adrián |e verfasserin |4 aut | |
| 700 | 1 | |a López-González, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Inga-Saavedra, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Montero, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Barneto, Isidoro |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-España, Mª Auxiliadora |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz, Estela |e verfasserin |4 aut | |
| 700 | 1 | |a Ruza, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Armenta, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Palacios, Amalia |e verfasserin |4 aut | |
| 700 | 1 | |a De La Haba-Rodríguez, Juan R |e verfasserin |4 aut | |
| 700 | 1 | |a Aranda, Enrique |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuro-oncology |d 1993 |g (2024) vom: 27. März |w (DE-627)NLM012591793 |x 1573-7373 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:27 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11060-024-04618-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 27 |c 03 | ||